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Objectives: We aimed to evaluate the safety and efficacy of the dedicated Tryton side branch
(SB) stent for the treatment of true bifurcations involving large SBs.
Background: Bifurcation lesions are associated with lower procedural success and a higher risk
of adverse cardiac events. Provisional stenting (PS) is currently the default approach for the
treatment of bifurcation lesions. The Tryton stent is a dedicated bifurcation stent system for the
treatment of true bifurcation lesions.
Methods: We performed an individual-patient-data pooled post-hoc analysis of the Tryton Piv-
otal randomized controlled trial and post-approval Confirmatory Study. Only patients with true
bifurcations involving a SB ≥ 2.25 mm in diameter were included. The primary endpoint was
non-inferiority of Tryton compared with PS for target vessel failure (TVF) at 1 year.
Results: Of the 411 patients meeting the criteria for enrolment, 287 patients were treated with
the Tryton stent and 124 with PS. Procedural success was higher in the Tryton group (95.4 ver-
sus 82.3%, P < 0.0001). TVF at 1 year was 8.1% in the Tryton group and 9.7% in the PS group,
meeting the pre-specified criteria for non-inferiority established for the randomized controlled
trail (pnon-inferiority = 0.02). At 9-month angiographic follow-up, SB diameter stenosis was signifi-
cantly lower in the Tryton group (29.3  21.9 versus 41.1  17.5, P = 0.0008) and in-segment
binary restenosis (diameter stenosis ≥ 50%) was higher in the PS group (19.0 versus 34.2%,
respectively, P = 0.052).
Conclusions: In patients with true bifurcations involving a large SB, treatment with the Tryton
SD Stent was clinically non-inferior to PS and showed favorable angiographic outcomes.
KEYWORDS
angioplasty, bifurcation, drug-eluting stent, percutaneous coronary intervention, provisional
1 | INTRODUCTION
Percutaneous coronary intervention of bifurcation lesions is techni-
cally challenging and is associated with lower procedural success rates
and higher risk for adverse cardiac events.1,2 Multiple randomized
controlled trials (RCTs) have suggested that patients with bifurcation
lesions do not benefit from a systematic two-stent strategy, and pro-
visional stenting (PS) has been widely accepted as the gold standard
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for the treatment of most bifurcation lesions.3–7 The advantage of the
PS strategy has been attributed to less procedure-related myocardial
infarction (MI) as well as decreased device-related clinical events at
follow-up;1 however, PS may require crossover to a second stent in
more than one-third of cases,5,8,9 with failure to deliver the second
stent in approximately 10%.10 Previous RCTs indicating that the PS
should be the preferred and default strategy may be limited, as most
of them included all bifurcations irrespective of Medina class11 or side
branch (SB) size. An exception is a study by Hildick-Smith et al.12 who
showed similar outcomes between PS to Culotte strategy specifically
in patients with true bifurcation lesions and large SB. On the other
hand, several other studies, including meta-analyses, have recently
suggested that a dedicated two-stent strategy is associated with a
lower need for revascularization in true bifurcation lesions with large
SB, compared with the PS technique1,13
We therefore performed an individual-patient-data pooled analysis of
the combined data from the Tryton Pivotal RCT and Confirmatory Study
to examine the safety and efficacy of the Tryton SB Stent (TrytonMedical,
Durham, North Carolina) for the treatment of true bifurcation lesions with
SB ≥2.25 mm by quantitative coronary angiography (QCA) using a con-
temporary definition of PPMI.
2 | METHODS
2.1 | Study population
Inclusion criteria for the Tryton RCT and Tryton Confirmatory Study were
the same and have been described previously.14,15 In short, patients with
symptoms or objective evidence of ischemia with a ≥ 50% narrowing in
both main branch (MB) and SB with Medina classification 1,1,1; 1,0,1; or
0,1,111 (true bifurcation) located in a de novo native coronary artery with
an SB 2.5–3.5 mm in diameter and a MB 2.5–4.0 mm in diameter were
enrolled. Lesion length was restricted to ≤28 mm in the MB (treatable
with a single stent) and ≤ 5 mm in the SB. Lesion evaluation was based on
visual estimates of the baseline angiography. Important exclusion criteria
were (1) ST-segment elevationMI within 72 hr or non–ST-segment eleva-
tion MI within 7 days preceding the index procedure; (2) left ventricular
ejection fraction <30%; (3) impaired renal function (serum creatinine >2.5
mg/dL or > 221 mmol/L) or current dialysis treatment; (4) left main coro-
nary artery disease (protected or unprotected); (5) trifurcation lesions;
(6) a total occlusion of the target vessel (MB or SB); (7) severely calcified
lesion(s); (8) the presence of excessive tortuosity; and (9) angiographic evi-
dence of thrombus. Included in this analysis were “lead in” as well as ran-
domized patients from the Tryton Pivotal RCT as long as they had true
bifurcation lesions with an SB ≥2.25 mm assessed by QCA (~2.5 mm per
visual estimate) and patients enrolled in the Tryton Confirmatory Study.
2.2 | Study device and procedure
The Tryton SB Stent is a dedicated bare metal, cobalt chromium, thin
strutted SB ostial protection stent mounted on a standard stent deliv-
ery balloon. The Tryton has 3 zones: (1) An SB zone (5.5–6.5 mm) to
be deployed within the SB; (2) a transition zone (4.5 mm) to be posi-
tioned at the SB ostium; and (3) an MB zone (8 mm).14–16
The implantation technique involves lesion preparation (pre-dilation
of MB and SB), placement of the bifurcation stent into the SB, and place-
ment of a commercially available DES within the MB. Simultaneous or
sequential final kissing balloon (FKB) inflation is then performed. Patients
randomized to the provisional PCI strategy underwent PCI per standard
operator technique, with FKB post-dilation.
2.3 | Study design
The TRYTON Pivotal RCT design has been previously described in detail.14
Briefly, it was a prospective, multicenter, single-blind RCT that enrolled
704 patients. After completion of the diagnostic angiogram and confirma-
tion of subject eligibility, patients were randomly assigned with the use of
a computer-generated scheme, blocked separately at each participating
site, and stratified by MB drug-eluting stent use and clinical site.
The Tryton Confirmatory Study15 was a prospective, single-arm
extension of the Tryton Pivotal RCT that enrolled an additional
133 patients treated with the Tryton and an approved drug-eluting
stent in the MB. Both studies were approved by the institutional
review board at each participating site, and all patients provided writ-
ten informed consent.
All serious adverse events were adjudicated by an independent
clinical events committee (Harvard Cardiovascular Research Institute,
Boston, Massachusetts). A data and safety monitoring board had
access to all study data. All data were analyzed by independent con-
sulting biostatisticians. An independent angiographic core laboratory
(Cardiovascular Research Foundation, New York, New York) analyzed
all angiograms using a conventional single-vessel algorithm analysis.
All patients were required to receive dual antiplatelet therapy (unless
they developed contraindications) for 12 months. Clinical assessment
was performed at 30 days, 9 months, and 12 months post-enrollment.
2.4 | Study endpoints
The primary endpoint of this study was the rate of target vessel failure
(TVF), defined as the composite of cardiac death, target vessel MI (The
Society for Cardiovascular Angiography and Interventions [SCAI] defini-
tion17), and clinically driven target vessel revascularization in the MB or
SB at 1 year. Pre-specified additional clinical secondary endpoints
included the following: The rates of device success (<30% residual ste-
nosis within the SB), lesion success (<50% residual stenosis using any
percutaneous method), and procedural success (lesion success without
the occurrence of in-hospital major adverse cardiac events [MACEs;
death, MI, emergent coronary artery bypass grafting, clinically driven
target lesion revascularization]); the rate of all-cause and cardiac mortal-
ity; the rate of Academic Research Consortium–defined stent thrombo-
sis,18 and the rate of target lesion revascularization. The secondary
angiographic endpoints were SB in-segment %DS of the bifurcation
stent compared with SB balloon angioplasty and binary restenosis
(DS ≥50%) of the SB at 9-month angiographic follow-up.
2.5 | Statistical analysis
Continuous variables are reported as mean and SD, and compared by
the Student t test. Categorical variables are reported as percentage
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and frequency, and compared by the χ2 test or Fisher exact test, as
appropriate. Time-to-event variables are reported as Kaplan–Meier
failure estimates and number of events, and compared by the log-rank
test. The primary endpoint of TVF at 1 year was analyzed using bino-
mial proportions, and the remainder of the endpoints is reported as
binary. The differences in event rates between the two treatments
arms (Tryton versus PS) were calculated along with a two-sided 95%
CI of the difference. The CI was calculated by the Z-test with continu-
ity correction. If the upper bound of this CI is <5.5% (the pre-specified
non-inferiority margin), then we declare that Tryton is non-inferior to
PS with respect to the primary endpoint. Analysis of the primary end-
point was performed on subjects with 365  30 days of follow-up or
an adjudicated event. All tests were two-sided, and P < 0.05 was con-
sidered statistically significant. Statistical analyses were performed
with SAS version 9.4 (SAS Institute, Cary, North Carolina).
3 | RESULTS
3.1 | Patient and procedures
A total of 902 patients were enrolled to the Tryton studies, of those,
411 (45.6%) patients fulfilled the entry criteria for this analysis:
287 patients treated with the Tryton SB Stent (155 RCT and 132 con-
firmatory study) and 124 patients randomized to PS from the RCT.
Baseline clinical characteristics of the study population according to
treatment are presented in Table 1. Baseline clinical characteristics
were similar between treatment groups.
Procedural characteristics are presented in Table 2. Procedure
duration, fluoroscopy duration, and use of contrast media and lesion
preparation was greater in the Tryton group than in the PS group. The
Tryton stent was successfully delivered in 98.3% (282/287) of cases,
and FKB inflation was performed more frequently in the Tryton group
(97.2 versus 91.9%, p = .02).
Angiographic characteristics and results are presented in Table 3.
There were no differences in PCI location, Medina classification, or
MB angiographic findings. In the SB, the baseline %DS was greater in
the Tryton group (61.6  12.1 versus 57.5  10.8%, P = 0.001).
Post-PCI the residual MB minimum lumen diameter (MLD) was similar,
but %DS was higher in the Tryton group compared with the PS group
(11  7.9 versus 9.1  7.3%, P = 0.02), while in the SB both the MLD
(2.3  0.32 versus 1.7  0.5%, P < 0.0001) and residual DS (11.2 
8.7 versus 32.4  18.2%, P < 0.0001) were improved in the Tryton
group. Correspondingly, device success (<30% DS in SB), lesion suc-
cess (<50% DS in SB), and procedural success (<50% DS in SB without
in-hospital MACE) were significantly higher in the Tryton group com-
pared with the PS group.
3.2 | Clinical outcomes
There was no difference in TVF (3.1 versus 2.4%, P = 0.69), TLF
(3.1 versus 2.4%, P = 0.69), MACE (4.2 versus 2.4%, P = 0.38), or
their respective individual components 30 days post-procedure
between the Tryton and PS groups (Table 4). Similarly, there was no
difference in TVF (8.1 versus 9.7%, P = 0.61) (Figure 1), TLF (8.1 ver-
sus 8.1%, P = 0.97), MACE (10.9 versus 9.7%, P = 0.70), or their
respective individual components 1-year post-procedure between
TABLE 1 Baseline patient characteristics
Pooled Tryton
(n = 287) PS (n = 124) P value
Age, year 64.8  10.3 64.7  8.9 0.91
Male sex 74.9% (215/287) 83.1% (103/124) 0.07
Smoking status
Current 18.8% (54/287) 13.8% (17/123) 0.22
Former 31.0% (89/287) 37.4% (46/123) 0.21
Never 50.2% (144/287) 48.8% (60/123) 0.80
Diabetes mellitus 26.9% (77/286) 29.0% (36/124) 0.66
Hypertension 76.0% (218/287) 77.2% (95/123) 0.78
Hypercholesterolemia 73.2% (208/284) 75.8% (91/120) 0.59
Family history of premature coronary artery disease 35.2% (81/230) 27.3% (30/110) 0.14
Prior MI 31.1% (89/286) 41.0% (50/122) 0.054
Prior percutaneous coronary intervention or coronary artery bypass grafting 40.4% (116/287) 43.5% (54/124) 0.55
Prior percutaneous coronary intervention 39.4% (113/287) 41.9% (52/124) 0.63
Prior coronary artery bypass grafting 2.4% (7/286) 3.2% (4/124) 0.65
Prior cerebrovascular accident or transient ischemic attack 8.7% (25/287) 5.7% (7/123) 0.30
History of congestive heart failure 4.5% (13/287) 0.0% (0/124) 0.02
Left ventricular ejection fraction, % 56.5  9.5 57.2  10.4 0.52
Clinical presentation
Stable angina 73.2% (210/287) 66.9% (83/124) 0.20
Unstable angina 19.9% (57/287) 25.0% (31/124) 0.24
Silent ischemia 7.9% (20/287) 8.1% (10/124) 0.27
Continuous data are presented as mean  SD and dichotomous data as % (n/N).
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the Tryton and PS groups. The Tryton was non-inferior to PS for
TVF at 1 year (pnon-inferiority = 0.02).
3.3 | Angiographic outcomes
A total of 132 patients (59 patients from the Tryton group and
73 patients from the PS group) underwent angiographic follow-up at
9 months. In the MB, reference vessel diameter and MLD were larger
in the Tryton group; however, there was no difference in DS (13.6 
11.7 versus 15.0  11.9%, P = 0.49) or in-segment binary restenosis
(8.5 versus 9.6% P = 0.82) between groups (Table 5). In the SB, refer-
ence vessel diameter was similar; however, in-segment MLD (1.75 
0.56 versus 1.44  0.42, P = 0.0004), DS (29.3  21.9 versus 41.1 
17.5%, P = 0.0008), and in-segment binary restenosis (19.0 versus
34.2%, P = 0.052) all favored the Tryton group compared with the PS
group.
4 | DISCUSSION
In this post-hoc analysis of the TRYTON Pivotal RCT and Tryton Con-
firmatory Study, we aimed to investigate the safety and efficacy of
the Tryton compared with PS for the treatment of patients with true
bifurcation lesions involving a large SB (≥2.25 mm by QCA). We report
the following important findings: (1) Bifurcation stenting using the
Tryton is highly feasible, with success in 98% of bifurcation lesions
attempted and with minimal increases in procedure duration, fluoros-
copy, and contrast use. (2) In true bifurcation lesions, despite tighter
stenoses at baseline, the Tryton SB Stent led to improved MLD, in-
segment DS, device success, lesion success, and procedural success
compared with PS immediately post-PCI. (3) There were no
TABLE 2 Procedural characteristics
Pooled Tryton
(n = 287) PS (n = 124) P value
Procedure duration,
min
68.6  32.4 56.6  27.4 0.0004
Access site
Femoral 60.3% (173/287) 59.7% (74/124) 0.91
Radial 39.4% (113/287) 40.3% (50/124) 0.86
Fluoroscopy duration,
min
24.3  13.7 18.8  11.9 0.0002
Contrast volume, mL 261.3  100.9 231.1  89.2 0.004
Pre-dilation of the
main vessel
90.9% (260/286) 79.8% (99/124) 0.002




98.3% (282/287) 0.8% (1/124)
2.5/2.5 × 19 mm 6.4% (18/282) 0.0% (0/1)
3.0/2.5 × 19 mm 36.5% (103/282) 0.0% (0/1)
3.5/2.5 × 19 mm 30.1% (85/282) 100.0% (1/1)
3.5/3.0 × 18 mm 25.2% (71/282) 0.0% (0/1)





49.5% (141/285) 53.2% (66/124) 0.49
Everolimus-eluting
PROMUS
29.5% (84/285) 36.3% (45/124) 0.17
Zotarolimus-eluting
resolute
7.4% (21/285) 3.2% (4/124) 0.11
Zotarolimus-eluting
endeavor
2.5% (7/285) 2.4% (3/124) 0.98
Sirolimus-eluting
CIPHER
3.5% (10/285) 4.8% (6/124) 0.52
Other 7.7% (22/285) 0.0% (0/124) 0.001
Stent diameter 3.17  0.35 3.13  0.36 0.20
FKB 97.2% (279/287) 91.9% (114/124) 0.02
SB stenting 2.1% (6/287)a 8.9% (11/124) 0.002
Continuous data are presented as mean  SD and dichotomous data as %
(n/N).
a Bailout stenting.
TABLE 3 Angiographic core laboratory assessed characteristics and
results
Pooled Tryton





72.5% (208/287) 68.5% (85/124) 0.42
Left circumflex 19.9% (57/287) 22.6% (28/124) 0.53
Right 7.3% (21/287) 8.9% (11/124) 0.59
Left main 0.3% (1/287) 0.0% (0/124) 0.51
Medina classification
1,1,1 53.0% (152/287) 46.0% (57/124) 0.19
1,0,1 17.1% (49/287) 19.4% (24/124) 0.58
0,1,1 30.0% (86/287) 34.7% (43/124) 0.34
MB
Lesions length, mm 16.5  7.3 15.9  6.6 0.44
Severe tortuosity 0.7% (2/287) 1.6% (2/124) 0.39
Severe calcification 6.6% (19/287) 4.0% (5/124) 0.30
Reference vessel
diameter, mm
3.09  0.37 3.06  0.33 0.40




2.51  0.21 2.52  0.22 0.52
Diameter stenosis, % 61.64  12.10 57.53  10.84 0.001
Post-percutaneous coronary intervention
MB
In-stent MLD, mm 2.8  0.39 2.8  0.33 0.86
In-stent diameter
stenosis, %








11.23  8.70 32.37  18.16 <0.0001
Device success 98.2% (280/285) 43.5% (54/124) <0.0001
Lesion success 98.9% (282/285) 83.9% (104/124) <0.0001
Procedural
success
95.4% (272/285) 82.3% (102/124) <0.0001
Continuous data are presented as mean  SD and dichotomous data as %
(n/N).
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differences in the clinical outcomes of TVF, TLF, or MACE between
the Tryton and PS groups at either 30 days or 1 year of clinical follow-
up. Thus, the study met its primary non-inferiority endpoint with
respect to TVF at 1 year comparing the Tryton and PS groups.
(4) Nine-month follow-up angiographic assessment identified a benefit
for the Tryton SB Stent compared with PS with respect to in-segment
MLD, DS, and in-segment binary restenosis.
Multiple studies have evaluated the safety and efficacy of a two-
stent strategy compared with PS,3–8,19 and most have failed to show
an advantage for a two-stent technique. A meta-analysis incorporating
the results of 9 RCTs including 2,569 patients reported that a two-
stent strategy had similar clinical safety (cardiac death and stent
thrombosis) and efficacy (TLR, target vessel revascularization) com-
pared with the PS strategy. Moreover, studies evaluating the perfor-
mance of dedicated bifurcation devices, such as the BiOSS LIM
stent20 also showed similar clinical outcomes in comparison to PS
approach.21,22
A recognized caveat of the 2-stent strategy reflected in the above
mentioned and other meta-analyses1,23,24 as well as in the TRYTON
Pivotal RCT is a higher incidence of MI, in particular PPMI. In this
regard, a number of key points should be considered. First, vessel
preparation, stenting, and post-dilation of the SB inevitably lead to
more vascular injury than PS and thus predispose a patient to PPMI.
Second, the definition of PPMI was not consistent throughout the dif-
ferent RCTs included in the various meta-analyses. As a result, the
dichotomization of PPMI may have a different impact in each of the
trials. Indeed, one of the primary reasons the Tryton Pivotal RCT failed
to meet its primary non-inferiority endpoint was an increase in PPMI
compared with PS; however, the definition of PPMI in the RCT was a
CK-MB ≥3× the upper limit of normal,5,7 a clinically outdated defini-
tion that has been supplanted by the more contemporary SCAI defini-
tion of PPMI.25 Indeed, in the current study using the SCAI definition,
we found no difference between the Tryton group and the PS group
in incidence of PPMI. Nevertheless, it remains unclear whether PPMI,





(n = 124) P value
30 days
TVF 3.1% (9) 2.4% (3) 0.69
MACEs 4.2% (12) 2.4% (3) 0.38
Death 0.0% (0) 0.0% (0) —
Cardiac 0.0% (1) 0.0% (0) —
Target vessel MI 2.8% (8) 2.4% (3) 0.83
Periprocedural MI 2.4% (7) 2.4% (3) 0.99
Any MI 3.5% (10) 2.4% (3) 0.57
Target vessel revascularization 1.4% (4) 0.0% (0) 0.19
Target lesion failure 3.1% (9) 2.4% (3) 0.69
Emergent coronary
artery bypass grafting
0.3% (1) 0.0% (0) 0.51
Target lesion revascularization 1.4% (4) 0.0% (0) 0.19
Stent thrombosis 1.4%(4) 0.0% (0) 0.19
1 year
TVF 8.1% (23) 9.7% (12) 0.61
MACEs 10.9% (31) 9.7% (12) 0.70
Death 2.1% (6) 0.8% (1) 0.35
Cardiac death 0.4% (1) 0.0% (0) 0.50
Target vessel MI 3.1% (9) 2.4% (3) 0.69
Any MI 4.2% (12) 3.2% (4) 0.64
Target vessel revascularization 6.8% (19) 7.3% (9) 0.87
MB 3.9% (11) 5.7% (7) 0.44
SB 4.3% (12) 2.4% (3) 0.37
Target lesion failure 8.1% (23) 8.1% (10) 0.97
Target lesion revascularization 6.0% (17) 5.7% (7) 0.86
MB 3.5% (10) 4.0% (5) 0.83
SB 4.3% (12) 2.4% (3) 0.37
Stent thrombosis 1.4% (4) 0.0% (0) 0.19
Dichotomous data are presented as % (n).
FIGURE 1 One-year target lesion failure: Tryton versus
PS. Abbreviations: CI, confidence interval; HR, hazard ratio [Color
figure can be viewed at wileyonlinelibrary.com]
TABLE 5 Angiographic outcomes at 9 months
Pooled Tryton




3.11  0.34 2.98  0.31 0.03
In-segment MLD 2.30  0.55 2.19  0.47 0.23
In-stent MLD 2.68  0.47 2.53  0.40 0.05
In-stent diameter
stenosis, %
13.61  11.70 15.04  11.93 0.49
Binary restenosis
In-segment 8.5% (5/59) 9.6% (7/73) 0.82




2.47  0.27 2.45  0.26 0.66
In-segment MLD 1.75  0.56 1.44  0.42 0.0004
Diameter stenosis, % 29.34  21.94 41.14  17.51 0.0008
Binary restenosis
In-segment 19.0% (11/58) 34.2% (25/73) 0.052
In-stent 14.0% (8/57) … …
Continuous data are presented as mean  SD and dichotomous data as %
(n/N).
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and more specifically PPMI from the SB in bifurcation PCI, is associ-
ated with clinically significant myocardial damage that impacts TLF.
Another factor that may influence not only the rate of PPMI but
also TLF is the diameter of the SB. In the subgroup analysis of patients
with large SBs from the meta-analysis mentioned earlier,1 PS was
associated with higher risk of target vessel revascularization and MB
restenosis compared with a two-stent strategy, suggesting a possible
advantage to the complex approach in patients with large SBs. Indeed,
a recent study identified that ~30% of first diagonals carry a func-
tional myocardial mass of ≥10%,26 equating to a degree of ischemia
that may impact cardiac death and MI.27 Considering that 72.5% of
patients in the Tryton group in this study involved an LAD diagonal,
the benefits of greater procedural success and DS at follow-up could
thus have important clinical implications.
Notably, procedure duration was ~12 min longer, fluoroscopy was
~5.5 minutes longer, and contrast utilization was ~30 mL greater in the
Tryton group. This could actually be expected when comparing two-stent
strategy with PS. Considering that the use of intravascular imaging
increases procedure duration by ~15 min28 and that there were no epi-
sodes of acute renal failure in the Tryton group, we believe that this find-
ing is probably of limited clinical significance. Moreover, procedural
duration and contrast used in the Tryton group were comparable to those
reported in other bifurcation studies evaluating two stents techniques.
Several limitations of this study should be acknowledged. First,
despite including the initial intended population of the Tryton Pivotal
RCT, our study may be subject to selection bias as the study popula-
tion includes a non–pre-specified subgroup of the RCT as well as
patients taking part in the non-randomized Confirmatory Study. Sec-
ond, the inclusion of patients with SB ≥2.25 mm according to QCA
should be considered as an extrapolation of what should be visually
assessed as a ≥2.5-mm SB. Third, only short lesions (<5 mm) with DS
>50% met the inclusion criteria for the Tryton studies, and whether
these conclusions would remain valid with longer lesions or wire-
assessed physiologically significant disease of the SB requires further
investigation. Moreover, the definition of procedural success was
based on angiographic assessment of SB residual stenosis. The func-
tional and clinical significance of higher procedural success in the Try-
ton group according to this definition is not certain. Fourth, while FKB
was required per protocol in the PS group, the clinical benefit of such
an approach have been recently challenged.29,30 Finally, the current
version of the Tryton is a bare metal stent; whether a drug-eluting
version will increase its beneficial effect remains to be determined.
5 | CONCLUSIONS
In patients with true bifurcations and large SBs enrolled in the Tryton
Pivotal RCT and the Confirmatory Study, treatment with the Tryton
SB Stent was associated with non-inferior 1-year clinical outcomes
and favorable angiographic results compared with PS.
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